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Angiogenesis is essential for tumor growth,[@B1] and it has been shown that anti-angiogenic therapy has been proven to be effective in several cancers such as colorectal cancer[@B2],[@B3] and hepatocellular carcinoma (HCC).[@B4] Currently available antiangiogenic cancer chemotherapy targets the vascular endothelial growth factor (VEGF) pathway by VEGF monoclonal antibody (bevacizumab)[@B3] or multi-targeted receptor tyrosine kinase inhibitors (sorafenib).[@B4] Hypoxia-inducible factor 1 (HIF-1) is a heterodimer protein which is composed of oxygen-regulated HIF-1α subunit and constitutively expressed HIF-1β subunit.[@B5],[@B6] Under normoxic condition, the degradation of HIF-1α subunit is facilitated by ubiquitination following the hydroxylation of proline residue(s). However, under hypoxic condition, stability of HIF-1α increases due to suppressed proline hydroxylation, leading to increased transcription of genes associated with adaptive homeostatic response to hypoxia such as erythropoiesis, glucose metabolism and angiogenesis.[@B7] In addition to intratumoral hypoxia, loss of function of tumor-suppressor genes also contributes to over-expression of HIF-1α in various human cancers.[@B6] HIF-1 is a key regulatory factor for angiogenesis in response to hypoxia: it induces expression of angiogenic growth factors such as VEGF, stromal derived factor 1, angiopoietin 2, placental growth factor, platelet-derived growth factor B and stem cell factor.[@B8] Many human cancers over-express HIF-1α, and expression of HIF-1α is associated with poor prognosis.[@B6],[@B9] In hepatitis B virus-associated HCC, high expression of HIF-1α is found in half of tumor specimens and correlated with venous invasion and lymph node invasion.[@B10] These findings suggest the possibility of HIF-1α as a novel therapeutic target in HCC.

In the current issue, Choi et al. suppressed HIF-1α by adenovirus-mediated small hairpin RNA and observed that proliferation of hepatoma cell lines was suppressed and the new vessel formation by vascular endothelial cells was inhibited.[@B11] This suppressive effect against hepatoma cells is concordant with the report by WeiXing et al. which knocked down HIF-1α by antisense oligonucleotide.[@B12] In the current study, however, the mechanisms by which HIF-1α directly inhibits the proliferation of hepatoma cell lines were not examined. In hypoxic state, HIF-1 can either induce or inhibit apoptosis.[@B13] Moreover, a recent report shows that knock-down of HIF-1α causes reciprocal increase of HIF-2α and vice versa, leading to attenuated apoptosis in HepG2 cells.[@B14] Therefore, further studies are warranted to examine the effects of HIF-1α on the apoptosis and proliferation of HCC in hypoxic state.

Recent reports including this study by Choi et al. have demonstrated that knock-down of HIF-1α by small interfering RNA[@B15] or short hairpin RNA can disrupt angiogenesis by HUVEC cells. However, the therapeutic potential of anti-angiogenic effect by targeting HIF-1 needs to be further validated in animal HCC models. One recent study targeting HIF-1α showed suppressed tumor growth and microvessel density in a murine subcutaneous HCC model.[@B16] However, two reports assessing the effect of HIF-1α on the tumor growth in orthotopic hepatoma models showed conflicting results.[@B17],[@B18] These results imply that the action of HIF-1 may be influenced by the types of tumor cells and/or the stromal components of the tumor.[@B9] Further animal studies are also warranted to examine the efficacy of combination therapy that includes HIF-1α targeting and conventional types of anti-cancer drugs.
